NIH Researchers Identify Novel "Superagonist" Opioid DFNZ with High Potency and Reduced Addiction Risk
NIH researchers discover DFNZ, a "superagonist" opioid that provides strong analgesia in animal models without causing respiratory depression or dependency.
By: AXL Media
Published: Apr 2, 2026, 4:38 AM EDT
Source: Information for this report was sourced from National Institutes of Health (NIH).
HEADLINE
NIH Researchers Identify Novel "Superagonist" Opioid DFNZ with High Potency and Reduced Addiction Risk
SUMMARY
Scientists at the National Institutes of Health have discovered DFNZ, a synthetic opioid metabolite that provides robust pain relief in animal models without causing the life-threatening respiratory depression or high addiction potential typical of traditional opioids. The study, published in Nature, suggests that this "superagonist" could revolutionize the treatment of chronic pain and opioid use disorder by decoupling high-efficacy analgesia from its dangerous side effects.
CONTENT
Revisiting a Shelved Class of Potent Synthetics
Categories
Topics
Related Coverage
- Clinical Trial Reveals Weekly Buprenorphine Injections Significantly Outperform Daily Sublingual Doses for Pregnant Patients Seeking Opioid Abstinence
- NIH Clinical Trial Validates Weekly Injectable Buprenorphine as Superior Treatment for Opioid Use Disorder During Pregnancy
- New Research Reveals Coastal Flood Risks May Be Underestimated Due to a 27-Centimeter Global Sea Level Baseline Error
- Former NIH Director Dr. Francis Collins Receives Highest Scientific Honor from Center for BrainHealth